Crispr Cash vs Accounts Payable Analysis

CRSP Stock

USD 46.29 0.97 2.05%

Crispr Therapeutics financial indicator trend analysis is way more than just evaluating Crispr Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crispr Therapeutics is a good investment. Please check the relationship between Crispr Therapeutics Cash and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Cash vs Accounts Payable

Cash vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crispr Therapeutics Cash account and Accounts Payable. At this time, the significance of the direction appears to have weak relationship.

The correlation between Crispr Therapeutics' Cash and Accounts Payable is 0.31. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Crispr Therapeutics AG, assuming nothing else is changed. The correlation between historical values of Crispr Therapeutics' Cash and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Crispr Therapeutics AG are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Cash i.e., Crispr Therapeutics' Cash and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.31

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash

Cash refers to the most liquid asset of Crispr Therapeutics, which is listed under current asset account on Crispr Therapeutics AG balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Crispr Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Crispr Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Accounts Payable

An accounting item on the balance sheet that represents Crispr Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Crispr Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Crispr Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

As of 11/21/2024, Tax Provision is likely to grow to about 3 M, while Selling General Administrative is likely to drop slightly above 62.4 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	539.6M	563.3M	463.5M	279.2M
Cost Of Revenue	101.2M	110.3M	130.3M	113.9M

Total Operating Expenses Cost Of Revenue

Crispr Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.94	0.99	1.0	-0.1	0.95	-0.47	-0.73	0.73	0.68	0.9	0.98	0.95	1.0	0.37	0.92	0.94	0.81	0.76	0.93	0.91	0.45	1.0	-0.54	-0.89	0.91
Other Current Liab	0.94		0.93	0.95	-0.2	0.88	-0.52	-0.58	0.58	0.71	0.82	0.94	0.87	0.95	0.18	0.79	0.89	0.72	0.84	0.85	0.83	0.22	0.94	-0.67	-0.78	0.8
Total Current Liabilities	0.99	0.93		0.99	-0.09	0.94	-0.46	-0.77	0.75	0.67	0.9	0.97	0.94	0.99	0.37	0.93	0.94	0.81	0.78	0.94	0.92	0.45	0.99	-0.54	-0.91	0.93
Total Stockholder Equity	1.0	0.95	0.99		-0.13	0.95	-0.5	-0.72	0.71	0.7	0.88	0.98	0.95	1.0	0.36	0.91	0.94	0.78	0.76	0.93	0.89	0.44	1.0	-0.56	-0.89	0.91
Other Liab	-0.1	-0.2	-0.09	-0.13		-0.16	-0.21	0.11	-0.13	0.14	-0.18	-0.07	-0.11	-0.09	-0.16	0.14	-0.21	0.24	-0.07	-0.15	0.13	-0.08	-0.09	0.42	-0.03	0.15
Net Tangible Assets	0.95	0.88	0.94	0.95	-0.16		-0.4	-0.84	0.86	0.66	0.94	0.92	0.99	0.94	0.59	0.88	0.91	0.76	0.71	0.99	0.86	0.61	0.95	-0.56	-0.95	0.88
Net Debt	-0.47	-0.52	-0.46	-0.5	-0.21	-0.4		0.13	0.0	-0.95	-0.12	-0.55	-0.44	-0.53	0.16	-0.57	-0.43	-0.12	-0.52	-0.36	-0.25	0.08	-0.51	0.56	0.4	-0.59
Retained Earnings	-0.73	-0.58	-0.77	-0.72	0.11	-0.84	0.13		-0.95	-0.39	-0.84	-0.67	-0.82	-0.7	-0.77	-0.78	-0.77	-0.66	-0.53	-0.9	-0.73	-0.77	-0.72	0.39	0.91	-0.77
Accounts Payable	0.73	0.58	0.75	0.71	-0.13	0.86	0.0	-0.95		0.31	0.91	0.64	0.83	0.69	0.86	0.71	0.72	0.73	0.5	0.9	0.77	0.84	0.71	-0.33	-0.89	0.71
Cash	0.68	0.71	0.67	0.7	0.14	0.66	-0.95	-0.39	0.31		0.41	0.74	0.69	0.73	0.09	0.74	0.64	0.36	0.67	0.63	0.49	0.15	0.72	-0.66	-0.65	0.76
Non Current Assets Total	0.9	0.82	0.9	0.88	-0.18	0.94	-0.12	-0.84	0.91	0.41		0.84	0.91	0.87	0.6	0.79	0.86	0.83	0.69	0.95	0.9	0.6	0.88	-0.42	-0.91	0.8
Non Currrent Assets Other	0.98	0.94	0.97	0.98	-0.07	0.92	-0.55	-0.67	0.64	0.74	0.84		0.95	0.99	0.27	0.89	0.9	0.74	0.71	0.9	0.85	0.34	0.98	-0.5	-0.85	0.9
Other Assets	0.95	0.87	0.94	0.95	-0.11	0.99	-0.44	-0.82	0.83	0.69	0.91	0.95		0.95	0.55	0.88	0.89	0.75	0.66	0.98	0.85	0.57	0.95	-0.5	-0.94	0.89
Cash And Short Term Investments	1.0	0.95	0.99	1.0	-0.09	0.94	-0.53	-0.7	0.69	0.73	0.87	0.99	0.95		0.33	0.91	0.93	0.79	0.77	0.92	0.9	0.4	1.0	-0.56	-0.88	0.91
Net Receivables	0.37	0.18	0.37	0.36	-0.16	0.59	0.16	-0.77	0.86	0.09	0.6	0.27	0.55	0.33		0.4	0.4	0.42	0.12	0.62	0.43	0.96	0.36	-0.18	-0.63	0.38
Common Stock Total Equity	0.92	0.79	0.93	0.91	0.14	0.88	-0.57	-0.78	0.71	0.74	0.79	0.89	0.88	0.91	0.4		0.88	0.74	0.76	0.88	0.84	0.5	0.92	-0.46	-0.93	1.0
Common Stock Shares Outstanding	0.94	0.89	0.94	0.94	-0.21	0.91	-0.43	-0.77	0.72	0.64	0.86	0.9	0.89	0.93	0.4	0.88		0.73	0.79	0.91	0.84	0.48	0.94	-0.69	-0.89	0.88
Non Current Liabilities Total	0.81	0.72	0.81	0.78	0.24	0.76	-0.12	-0.66	0.73	0.36	0.83	0.74	0.75	0.79	0.42	0.74	0.73		0.58	0.76	0.98	0.51	0.8	-0.23	-0.78	0.73
Other Current Assets	0.76	0.84	0.78	0.76	-0.07	0.71	-0.52	-0.53	0.5	0.67	0.69	0.71	0.66	0.77	0.12	0.76	0.79	0.58		0.71	0.68	0.15	0.76	-0.74	-0.74	0.78
Other Stockholder Equity	0.93	0.85	0.94	0.93	-0.15	0.99	-0.36	-0.9	0.9	0.63	0.95	0.9	0.98	0.92	0.62	0.88	0.91	0.76	0.71		0.86	0.63	0.93	-0.54	-0.97	0.89
Total Liab	0.91	0.83	0.92	0.89	0.13	0.86	-0.25	-0.73	0.77	0.49	0.9	0.85	0.85	0.9	0.43	0.84	0.84	0.98	0.68	0.86		0.51	0.9	-0.35	-0.86	0.83
Short Long Term Debt	0.45	0.22	0.45	0.44	-0.08	0.61	0.08	-0.77	0.84	0.15	0.6	0.34	0.57	0.4	0.96	0.5	0.48	0.51	0.15	0.63	0.51		0.44	-0.18	-0.66	0.47
Total Current Assets	1.0	0.94	0.99	1.0	-0.09	0.95	-0.51	-0.72	0.71	0.72	0.88	0.98	0.95	1.0	0.36	0.92	0.94	0.8	0.76	0.93	0.9	0.44		-0.56	-0.89	0.92
Short Term Debt	-0.54	-0.67	-0.54	-0.56	0.42	-0.56	0.56	0.39	-0.33	-0.66	-0.42	-0.5	-0.5	-0.56	-0.18	-0.46	-0.69	-0.23	-0.74	-0.54	-0.35	-0.18	-0.56		0.52	-0.48
Intangible Assets	-0.89	-0.78	-0.91	-0.89	-0.03	-0.95	0.4	0.91	-0.89	-0.65	-0.91	-0.85	-0.94	-0.88	-0.63	-0.93	-0.89	-0.78	-0.74	-0.97	-0.86	-0.66	-0.89	0.52		-0.94
Common Stock	0.91	0.8	0.93	0.91	0.15	0.88	-0.59	-0.77	0.71	0.76	0.8	0.9	0.89	0.91	0.38	1.0	0.88	0.73	0.78	0.89	0.83	0.47	0.92	-0.48	-0.94

Click cells to compare fundamentals

Crispr Therapeutics Account Relationship Matchups

Crispr Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1B	1.8B	2.8B	2.2B	2.2B	1.3B
Other Current Liab	41.7M	49.6M	79.0M	61.9M	34.9M	30.6M
Total Current Liabilities	57.1M	94.3M	119.9M	121.1M	108.8M	63.5M
Total Stockholder Equity	939.4M	1.7B	2.4B	1.9B	1.9B	1.0B
Other Liab	26.2M	19.4M	19.7M	18.3M	16.5M	15.6M
Net Tangible Assets	939.2M	1.7B	2.4B	1.9B	2.2B	2.3B
Net Debt	(891.2M)	(1.1B)	(698.0M)	32.1M	(150.8M)	(158.4M)
Retained Earnings	(224.7M)	(573.6M)	(195.9M)	(846.1M)	(999.7M)	(949.7M)
Accounts Payable	5.9M	9.1M	14.8M	27.4M	38.1M	40.1M
Cash	943.8M	1.2B	923.0M	211.9M	389.5M	528.6M
Non Current Assets Total	79.2M	111.3M	334.4M	390.0M	321.5M	337.6M
Non Currrent Assets Other	6.1M	18.1M	22.2M	16.3M	13.6M	9.7M
Other Assets	6.1M	18.1M	22.2M	16.3M	18.7M	19.7M
Cash And Short Term Investments	943.8M	1.7B	2.4B	1.8B	1.7B	1.1B
Net Receivables	99K	144K	305K	11.2M	200M	210M
Common Stock Total Equity	1.8M	2.3M	2.4M	2.4M	2.8M	1.6M
Common Stock Shares Outstanding	56.9M	65.9M	80.4M	77.7M	79.2M	57.1M
Liabilities And Stockholders Equity	1.1B	1.8B	2.8B	2.2B	2.2B	1.3B
Non Current Liabilities Total	70.2M	69.5M	232.5M	246.5M	238.0M	139.7M
Other Current Assets	43.7M	15.4M	29.7M	37.7M	14.4M	17.4M
Other Stockholder Equity	1.2B	2.2B	2.6B	2.7B	2.9B	3.0B
Total Liab	127.3M	163.7M	352.4M	367.6M	346.8M	203.2M
Total Current Assets	987.5M	1.7B	2.4B	1.9B	1.9B	1.1B
Accumulated Other Comprehensive Income	7K	(83K)	(5.1M)	(15.6M)	1.9M	2.0M
Short Term Debt	8.5M	22.7M	24.3M	31.7M	31.3M	26.8M
Intangible Assets	235K	180K	125K	71K	16K	15.2K
Common Stock	1.8M	2.3M	2.4M	2.4M	2.5M	1.7M
Property Plant And Equipment Net	72.8M	93.0M	312.0M	320.6M	305.9M	321.2M
Capital Surpluse	1.2B	2.2B	2.6B	2.7B	3.1B	3.3B
Property Plant And Equipment Gross	72.8M	93.0M	137.6M	163.6M	359.4M	377.3M
Property Plant Equipment	72.8M	42.2M	137.6M	163.6M	188.2M	197.6M
Current Deferred Revenue	960K	2.3M	1.0M	12.3M	4.1M	3.9M
Retained Earnings Total Equity	(224.7M)	(573.6M)	(195.9M)	(846.1M)	(761.5M)	(723.4M)
Non Current Liabilities Other	14.4M	69.5M	232.5M	6.0M	958K	910.1K
Net Invested Capital	939.4M	1.7B	2.4B	1.9B	1.9B	1.5B

Pair Trading with Crispr Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Crispr Stock

0.35	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.35	KTTA	Pasithea Therapeutics	Pair Corr
0.35	PALI	Palisade Bio	Pair Corr
0.33	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.

The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Crispr Stock Analysis

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC